--- title: "BioVie enters sales agreement for up to $6,464,341 of common stock" url: "https://aibio.space/news/biovie-enters-sales-agreement-up-6-464-341-common-stock/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-11" section: "Financings" tickers: "NASDAQ:BIVI" source: "https://www.sec.gov/Archives/edgar/data/1580149/000152013826000391/bivi-20260911_8k.htm" summary: "BioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commissio" --- By the aibio.space news desk. Sources - [BioVie Inc. 8-K (2026-09-14)](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000391/bivi-20260911_8k.htm) - [BioVie Inc. 10-K (2026-08-13): business](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/bivi-20260630_10kv8.htm) - [BioVie Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000332/) [BIVI](https://aibio.space/companies/biovie/) 2026-09-11 # BioVie enters sales agreement for up to $6,464,341 of common stock Tickers [BIVI](https://aibio.space/companies/biovie/) BioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commission on gross proceeds. ## Key facts - **Company**: BioVie Inc. (NASDAQ: BIVI) - **News type**: Financings - **Primary source**: [BioVie Inc. 8-K (2026-09-14)](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000391/bivi-20260911_8k.htm) *Midtown Manhattan and a downtown tower in haze. CC0, via rawpixel. The picture shows the field, not the companies named.* On September 11, 2026, BioVie Inc. entered into a sales agreement with A.G.P./Alliance Global Partners, under which BioVie may sell shares of its Class A common stock, from time to time, with an aggregate offering price of up to $6,464,341. The agreement is described in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1580149/000152013826000391/bivi-20260911_8k.htm) filed on September 14, 2026. BioVie's Class A common stock trades on Nasdaq under the symbol BIVI. ## The terms of the sales agreement The shares are offered under BioVie's Registration Statement on Form S-3 (File No. 333-296924). The registration statement was filed with the Securities and Exchange Commission on June 18, 2026, and was declared effective on June 29, 2026. A prospectus supplement was filed on September 11, 2026, and the filing says the placement shares are offered under the registration statement, its base prospectus and that supplement. A.G.P./Alliance Global Partners, which the filing calls the Agent, may sell the shares by any method deemed to be an at-the-market offering under Rule 415 of the Securities Act of 1933. That includes sales made directly on or through The Nasdaq Capital Market or any other existing trading market in the United States. The Agent may also sell shares in negotiated transactions with BioVie's prior approval. BioVie has no obligation to sell any shares and may suspend offers or terminate the agreement at any time. Under the agreement, BioVie pays the Agent a commission equal to 3.0% of the gross proceeds from shares sold through the Agent. BioVie also reimburses the Agent for certain specified expenses. Each party has indemnification obligations under the Securities Act. The offering ends when all shares are sold, when the registration statement expires on the third anniversary of its effective date, or when either party terminates. BioVie intends to use any proceeds for general corporate purposes. ## Who the filing names The filing names A.G.P./Alliance Global Partners as the only sales agent. It does not name any underwriter or any other placement agent. The 8-K does not name counsel to the Agent. Fennemore Craig, P.C. gave the opinion on the validity of the placement shares, which is filed as Exhibit 5.1, and gave its consent as Exhibit 23.1. The report is signed by Joanne Wendy Kim, BioVie's Chief Financial Officer. ## About BioVie BioVie describes itself in its annual report as a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its main drug candidate is bezisterim, also called NE3107, an investigational, orally administered small molecule that the company believes inhibits inflammation-driven insulin resistance. BioVie acquired the assets of NeurMedix, Inc., a related party, in June 2021. The company says bezisterim could address Alzheimer's disease, Parkinson's disease and Long COVID. In August 2026, BioVie reported topline results from its Phase 2b SUNRISE-PD trial (NCT06757010) in early-stage Parkinson's disease. The trial tested bezisterim at 20 mg twice daily in 57 patients who had not been treated with carbidopa/levodopa. The company said the results will inform the design of a potentially pivotal Phase 3 trial. The study was small and ran for 12 weeks, and the company itself calls its biomarker observations exploratory and says any effect on disease progression needs confirmation in future trials. It reported no severe or serious adverse events. ## Financial position For the fiscal year ended June 30, 2026, BioVie reported research and development expense of $14.0 million, compared with $9.3 million for the fiscal year ended June 30, 2025. The net loss was $22.1 million, compared with $17.5 million in the prior fiscal year. Cash from operations was negative $19.0 million in both years. The annual report was filed on August 13, 2026. According to the XBRL financial data, year-end cash and cash equivalents were $9.0 million at June 30, 2026, compared with $17.5 million at June 30, 2025. The $6,464,341 capacity is small beside that spending. Every share sold dilutes holders at whatever price the market gives, and the filing sets no price floor. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story BIVI BioVie Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/biovie-enters-sales-agreement-up-6-464-341-common-stock/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioVie enters sales agreement for up to $6,464,341 of common stock", 2026-09-11, https://aibio.space/news/biovie-enters-sales-agreement-up-6-464-341-common-stock/